Team

Aaron is a founder and Managing Partner of Scion. Over the past 15 years, he has specialized in founding, building and investing in life sciences companies, focused primarily on therapeutics. Aaron currently serves as a board member of Avalo Therapeutics (NASDAQ: AVTX). Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA), recently acquired by Eli Lilly (NASDAQ: LLY). Prior to launching Scion, he was a co-founder and founding board member of RayzeBio (acquired by Bristol Myers Squibb) and Tourmaline Bio (acquired by Novartis). Collectively, Aaron has been a founding investor/board member of six $1 billion plus M&A transactions totaling over $20B in total cash consideration.

From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment team, playing a leading role in launching seven ATP portfolio companies, serving on the Board of Directors of Akero Therapeutics (acquired by Novo Nordisk), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking.

Aaron received a B.S. in Finance and International Business from NYU’s Stern School of Business.